mRNA-1273.214 COVID-19 vaccine clinical trials
How each study uses mRNA-1273.214 COVID-19 vaccine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- mRNA-1273.214
- 7
Studies by the year they started
8 studies that test it; most in 2022 (6)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 6 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 2
ModernaTX, Inc. (6) · Murdoch Childrens Research Institute (1) · Sheba Medical Center (1)
Often tested with
Tested in the same studies.
mRNA-1345 respiratory syncytial virus vaccine (2) · 2019-nCoV Vaccine mRNA-1273 (1) · Elasomeran/Davesomeran (1) · mRNA-1010 influenza vaccine (1) · MRNA-1045 (1) · MRNA-1230 (1)
Studies
Open first, then newest update. How each study uses mRNA-1273.214 COVID-19 vaccine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- COVID-19 Booster Study in Healthy Adults in AustraliaActive, not recruitingPhase 3Murdoch Childrens Research InstituteNCT05658523Written as Bivalent ModernaHow we know
- A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of AgeCompletedPhase 3ModernaTX, Inc.NCT05330975Written as mRNA-1273.214How we know
- A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of AgeCompletedPhase 3ModernaTX, Inc.NCT05436834Written as mRNA-1273.214How we know
- Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in InfantsTerminatedPhase 2ModernaTX, Inc.NCT05584202Written as mRNA-1273.214How we know
- A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) VariantsCompletedPhase 2/3ModernaTX, Inc.NCT04927065Written as mRNA-1273.214How we know
- A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19CompletedPhase 2/3ModernaTX, Inc.NCT05249829Written as mRNA-1273.214How we know
- A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years OldCompletedPhase 1ModernaTX, Inc.NCT05585632Written as mRNA-1273.214How we know
- Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in AdultsCompletedPhase 2Sheba Medical CenterNCT05383560Written as mRNA-1273.214 VaccineHow we know
Given beside what is tested · 1 — mRNA-1273.214 COVID-19 vaccine is usual care or a partner of the new treatment
Codes
What other systems call mRNA-1273.214 COVID-19 vaccine · ClinicalTrials.gg INT001890
- MeSH (NLM) C000722752mRNA-1273.214 COVID-19 vaccineOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722752 | mRNA-1273.214 COVID-19 vaccine | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.